Details of the Drug-Related molecule(s) Interaction Atlas

SB 203186 Drug Info

SB 203186; SB-203186; 2-piperidin-1-ylethyl 1H-indole-3-carboxylate; Tocris-0785; NCGC00015921-01; Lopac-S-0443; Biomol-NT_000150; AC1MN68M; Lopac0_000347; GTPL255; BPBio1_000617; SCHEMBL1041116; CHEMBL1255781; ZINC14457; CHEBI:92477; BDBM85778; YGKPIROTKVQCCU-UHFFFAOYSA-N; CCG-204442; NCGC00024790-03; NCGC00015921-02; NCGC00024790-01; NCGC00024790-02; NCGC00015921-04; NCGC00015921-03; CAS_135938-17-9; (1-piperidinyl)ethyl 1h-indole 3-carboxylate; 2-(1-piperidyl)ethyl 1H-indole-3-carboxylate; 2-(1-Piperidyl)ethyl 1 H-indole-3-carboxy

Cross-matching ID

PubChem CID

3272300

ChEBI ID

CHEBI:92477

TTD Drug ID

DMNJ7LY

General Information of Drug (ID: DMNJ7LY)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting 5-HT 4 receptor (HTR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisapride	DMY7PED	Gastroesophageal reflux disease	DA22.Z	Approved	[2]
Tegaserod	DM3XYD1	Irritable bowel syndrome	DD91.0	Approved	[3]
R0-93877	DMM4U9G	Constipation	DD91.1	Approved	[4]
HTF 919	DM78G6F	Constipation	DD91.1	Approved	[1]
Mosapride	DM2VOQ3	N. A.	N. A.	Phase 4	[5]
Renzapride	DM7HQNX	Irritable bowel syndrome	DD91.0	Phase 3	[6]
Lintopride	DMSHGWN	Nausea	MD90	Phase 2	[7]
TD-8954	DM3C9NV	Gastrointestinal disease	DE2Z	Phase 2	[8]
SB-207266A	DM27KFY	Irritable bowel syndrome	DD91.0	Phase 2	[4]
YKP-GI	DM740LV	Constipation	DD91.1	Phase 2	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.
2	Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90.
3	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
4	Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
5	The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37.
6	Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
7	The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
8	The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25.
9	A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015 Apr;13(4):701-8.e1.